Live

Endpoints NewsThe state of consumer health Endpoints NewsQ&A: Novo research chief Petersen says streamlined R&D speeds discovery Endpoints NewsWave aims for monthly dosing with RNA editing treatment for AATD BioPharma DiveA migraine drugmaker heads to the public markets through reverse merger FierceBiotechFacing mounting China licensing costs, biopharma buyers turn to AI and local know-how to keep up FierceBiotechIncyte inks deal with Edison Scientific to train AI through drug discovery FierceBiotechClinical trial flaws ‘being scaled, not solved’ by AI: report Endpoints NewsFull-Life Technologies raises $150M; Quince's reboot with pulmonary drug FierceBiotechMerck inks Keytruda supply pact to support Exelixis’ colorectal cancer trial PharmaVoiceSummer reads with unexpected lessons for biopharma leaders BioWorldShanghai Meiyue Biotech discloses new EHMT2 inhibitors BioWorldConvalife Pharmaceuticals discovers new CFB inhibitors

Labiotech 19. Mai 2026

RAS inhibition enters its second wave

Delve into the field of RAS inhibitors, an area of biotechnology that is increasingly diversifying to tackle pancreatic cancer, among other cancers. The post RA...

Delve into the field of RAS inhibitors, an area of biotechnology that is increasingly diversifying to tackle pancreatic cancer, among other cancers. The post RAS inhibition enters its second wave appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.